Close menu




December 3rd, 2021 | 12:38 CET

BioNTech, Defence Therapeutics, QIAGEN - End in sight?

  • Biotechnology
Photo credits: pixabay.com

The federal and state governments have met and decided on a de facto lockdown for the unvaccinated. In the future, only vaccinated and recovered people will be allowed to shop in retail stores. The same applies to cinemas, theaters and restaurants. In addition, the unvaccinated will have to accept contact restrictions. According to the outgoing chancellor, this is an "act of national solidarity" and is necessary to get out of the current difficult situation - hard times, which the Omicron variant has just exacerbated. But according to US strategists, it is precisely the newly emerged mutant that could signal the approaching end of the Corona pandemic.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , QIAGEN NV EO -_01 | NL0012169213

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNTech - New target group

    According to Bloomberg, JP Morgan market strategists Marko Kolanovic and Brian Kaplan write in a published study that "Omicron could signal that the end of the pandemic is in sight." The experts base their thoroughly surprising thesis on historical patterns of virus development. Citing scientists, the strategists write that while the Omicron variant is more contagious, it causes less severe disease. If confirmed, "the Omicron variant could ultimately prove positive for risk markets, in the sense of hastening the end of the pandemic." The pandemic could then potentially change to make Corona "more like the seasonal flu," the authors said. Such a development would be consistent with historical patterns of previous viral pandemics.

    In contrast, Ugur Sahin, CEO of vaccine manufacturer BioNTech, sees a "tough four to five months" ahead for society. In addition to patience, he said, vaccinations are essential to defeating the fourth wave. In the process, a new target group has been tapped, children in the 5 to 11 age group. Even one week earlier than planned, on December 13, the first tranche of 2.4 million doses is to be delivered to Germany. We are talking about up to 13 million doses of the pediatric vaccine for the EU before the end of 2021.

    Defence Therapeutics - Visionary platform

    In contrast to BioNTech, with a market capitalization of USD 66.37 billion, Defence Therapeutics, with a stock market value of EUR 132.99 million, is still in the early stages of development. The Canadians are working to develop the next generation of vaccines and ADC products with their proprietary platform. At the core of the Defence Therapeutics platform is ACCUM technology, which enables precise transport of vaccine antigens or ADCs in the intact form to target cells. As a result, improved efficiency and efficacy against many diseases such as cancer and infections can be achieved. Having filed four new patents last year, the technologies of Defence have an increasing portfolio of intellectual property rights.

    In this context, the technology can be applied with particular precision in vaccine development. Research activities conducted by the Company have identified that adding Accum-bound antigens to allogeneic DCs (AccuVAC-D001) increases the therapeutic effect of the vaccine and achieves a survival rate of 70-80%, compared to the 0-20% achieved by current experimentally proven DC-based vaccines. After completing this study, Defence Therapeutics has signed an agreement with a cleanroom provider in Canada to conduct trial runs with its DC vaccine. The goal is to complete all required GLP studies by the first quarter of 2022 and to complete a Phase I trial against melanoma in the UK by mid-2022.

    In addition, all preclinical activities related to its COVID-19 vaccines have already been completed. The data obtained achieved high reactivity against all variants tested. The second vaccine formulation (DTC-IN003) is a vaccine that blocks transmission to stop infection. Also in development is a vaccine against human papillomavirus (HPV). The effect of the AccuVAC-PT009 vaccine is being compared to the commercially available Gardasil-9 vaccine in terms of immunogenicity. In addition, Defence is working on a second HPV-related vaccine that will specifically target cervical cancer.

    Through the Accum technology platform, the fields of application seem endless. However, it should not be forgotten that the Company is still in the early stages of development. Due to this, an entry at this early stage is extremely risky, but the opportunities are enormous if the innovative platform continues to develop positively.

    QIAGEN - A model of a good start

    The share of the provider of sample preparation and testing technologies for molecular diagnostics, academic research and the pharmaceutical industry has made a model run at the resistance level of EUR 48.00. A successful test should lift the share back towards the old high for the year at EUR 51.40.

    On the news side, the Company announced the CE mark of its QuantiFERON SARS-CoV-2 test, which can detect T-cell response to SARS-CoV-2 and determine immunity status following COVID-19 vaccination. The QuantiFERON SARS-CoV-2 assay is based on QIAGEN's QuantiFERON IGRA (Interferon-Gamma Release Assay) technology, recognized worldwide as an easy-to-use assay. Unlike other T-cell tests, the assay uses whole blood and does not require the purification of lymphocytes prior to T-cell detection.

    "T cells provide us with valuable insights into the immune response to COVID-19," said Jean-Pascal Viola, senior vice president and head of QIAGEN's Molecular Diagnostics business unit. "The better we understand this pandemic, the more likely we are to be able to deal with this threat worldwide, which will continue to be with us. We are excited to make a new contribution to measuring the immune response with QuantiFERON technology, which is essential for disease prevention and management."


    It is decided. The unvaccinated are marching into a de facto lockdown. In contrast, experts at JP Morgan see Omicron as a signal that the pandemic is weakening. According to policymakers and industry, the main tool continues to be vaccination and testing. BioNTech is the leader in this area, and Defence Therapeutics has enormous development potential with its platform. QIAGEN is interesting from a technical perspective.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read

    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.

    Read